Margaret A Shipp

Margaret A Shipp

UNVERIFIED PROFILE

Are you Margaret A Shipp?   Register this Author

Register author
Margaret A Shipp

Margaret A Shipp

Publications by authors named "Margaret A Shipp"

Are you Margaret A Shipp?   Register this Author

94Publications

3764Reads

17Profile Views

Reply to Z. Wu et al.

J Clin Oncol 2018 09 30;36(25):2657. Epub 2018 May 30.

Donna S. Neuberg, Dana-Farber Cancer Institute; and Harvard T.H. Chan School of Public Health, Boston, MA; Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9826
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9826DOI Listing
September 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 05 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855PMC
May 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):310-316

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142542PMC
December 2017

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

Blood 2017 11;130(21):2265-2270

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-06-781989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701523PMC
November 2017

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

J Clin Oncol 2017 Jul 25;35(19):2125-2132. Epub 2017 Apr 25.

Robert Chen, City of Hope National Medical Center, Duarte, CA; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Nathalie A. Johnson, Jewish General Hospital, Montreal, Canada; Pauline Brice, Hôpital Saint-Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; John Radford, The University of Manchester and Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Daniel Molin, Uppsala University, Uppsala, Sweden; Theodoros P. Vassilakopoulos, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; Akihiro Tomita, Nagoya University Graduate School of Medicine, Nagoya, Japan; Bastian von Tresckow, University Hospital Cologne, Cologne, Germany; Yinghua Zhang, Alejandro D. Ricart, and Arun Balakumaran, Merck, Kenilworth, NJ; Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843PMC
July 2017

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

J Clin Oncol 2016 11;34(31):3733-3739

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Vincent Ribrag and Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France; Pier Luigi Zinzani, Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy; John Kuruvilla, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Ellen S. Snyder, Alejandro D. Ricart, Arun Balakumaran, and Shelonitda Rose, Merck, Kenilworth, NJ; and Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.3467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791838PMC
November 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

J Clin Oncol 2016 08 6;34(23):2698-704. Epub 2016 Jun 6.

Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer Institute, Portland, OR; Ahmad Halwani, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Martin Gutierrez, Hackensack University Medical Center, Hackensack; Lili Zhu, Joseph F. Grosso, and M. Brigid Bradley Garelik, Bristol-Myers Squibb, Princeton, NJ; Michael M. Millenson, Fox Chase Cancer Center; Adam D. Cohen and Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; Daniel Lebovic, University of Michigan, Ann Arbor, MI; Madhav Dhodapkar, Yale Cancer Center, New Haven, CT; Ivan Borrello, Johns Hopkins University School of Medicine, Baltimore, MD; and John Timmerman, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019749PMC
August 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Proc Natl Acad Sci U S A 2016 May 9;113(21):5999-6004. Epub 2016 May 9.

Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, College Station, TX 77843;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1602069113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889388PMC
May 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

A roadmap for discovery and translation in lymphoma.

Blood 2015 Mar;125(13):2175-7

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-01-623777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375113PMC
March 2015

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

N Engl J Med 2015 Jan 6;372(4):311-9. Epub 2014 Dec 6.

From the Mayo Clinic, Rochester, MN (S.M.A.); Memorial Sloan Kettering Cancer Center (A.M.L., D.C.) and Weill Cornell Medical College (A.M.L.) - both in New York; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore (I.B.); University of Utah Huntsman Cancer Institute, Salt Lake City (A.H.); Oregon Health and Science University and the Knight Cancer Institute, Portland (E.C.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack (M.G.), and Bristol-Myers Squibb, Lawrenceville (L.Z., J.F.G., S.Y.K.) - both in New Jersey; Abramson Cancer Center, University of Pennsylvania (S.J.S.), and Fox Chase Cancer Center (M.M.M.) - both in Philadelphia; Dana-Farber Cancer Institute (G.J.F., B.C., M.A.S., P.A.) Brigham and Women's Hospital (S.J.R., A.H.L.), and Harvard Medical School (G.J.F., B.C., M.A.S., P.A., S.J.R., A.H.L.) - all in Boston; and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (J.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009PMC
January 2015

Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Clin Cancer Res 2014 May 7;20(10):2674-83. Epub 2014 Mar 7.

Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute; Section of Computational Biomedicine, Boston University School of Medicine; and Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084704PMC
May 2014

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

Cell 2014 Feb;156(4):744-58

Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 1428 Buenos Aires, Argentina; Laboratorio de Glicómica. Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, 1428 Buenos Aires, Argentina. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2014.01.043DOI Listing
February 2014

Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma.

Blood 2013 Apr 26;121(17):3431-3. Epub 2013 Feb 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-12-474569DOI Listing
April 2013

BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.

Mol Cell Biol 2013 Feb 10;33(4):845-57. Epub 2012 Dec 10.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00990-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571337PMC
February 2013

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Cancer Res 2013 Jan 29;73(1):86-96. Epub 2012 Oct 29.

Laboratorio de Glicómica Estructural y Funcional, IQUIBICEN-CONICET, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1260DOI Listing
January 2013

Molecular signatures define new rational treatment targets in large B-cell lymphomas.

Authors:
Margaret A Shipp

Hematology Am Soc Hematol Educ Program 2007 :265-9

Dana-Farber Cancer Institute, 44 Binney St., Rm. M513, Boston, MA 02115-6084, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2007.1.265DOI Listing
July 2009

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).

Clin Cancer Res 2006 Dec;12(23):7174-9

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1275DOI Listing
December 2006

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.

J Exp Med 2006 Feb;203(2):311-7

Institute for Cancer Genetics and 2The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20052204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118216PMC
February 2006

B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity.

J Biol Chem 2005 Oct 1;280(40):33756-65. Epub 2005 Aug 1.

Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M505408200DOI Listing
October 2005

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.

Blood 2005 Aug 26;106(4):1164-74. Epub 2005 Apr 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-02-0687DOI Listing
August 2005

Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass.

N Engl J Med 2005 Apr;352(16):1697-704

Division of Medical Oncology, Dana-Farber Cancer Institute, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc059006DOI Listing
April 2005

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.

Blood 2005 Jan 26;105(1):308-16. Epub 2004 Aug 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-01-0240DOI Listing
January 2005

Molecular diagnostics.

Hematology Am Soc Hematol Educ Program 2003 :279-93

Oregon Health and Sciences University, Department of Pathology, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2003.1.279DOI Listing
September 2004

The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity.

J Biol Chem 2003 Jun 1;278(24):21930-7. Epub 2003 Apr 1.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M301157200DOI Listing
June 2003

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.

Leuk Lymphoma 2002 Apr;43(4):793-7

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190290016908DOI Listing
April 2002

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

J Clin Oncol 2002 Mar;20(5):1288-94

Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.5.1288DOI Listing
March 2002